BS_KF0ZXDER
Meningioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Meningioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Meningioma
- overall_survival_months
- 52.135348226018394
- age_years
- 17.019
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.536
- INTERFERON_GAMMA_RESPONSE+0.476
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.429
- TNFA_SIGNALING_VIA_NFKB+0.426
- TGF_BETA_SIGNALING+0.419
- INFLAMMATORY_RESPONSE+0.415
- ALLOGRAFT_REJECTION+0.394
- ANDROGEN_RESPONSE+0.382
- IL6_JAK_STAT3_SIGNALING+0.375
- APOPTOSIS+0.372
Top 10 suppressed
- G2M_CHECKPOINT-0.320
- E2F_TARGETS-0.316
- HEDGEHOG_SIGNALING-0.314
- SPERMATOGENESIS-0.277
- WNT_BETA_CATENIN_SIGNALING-0.220
- PANCREAS_BETA_CELLS-0.183
- MITOTIC_SPINDLE-0.163
- MYC_TARGETS_V2-0.104
- DNA_REPAIR-0.065
- KRAS_SIGNALING_UP+0.064
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.927 |
| 2 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.922 |
| 3 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.899 |
| 4 | BS_53CTGDQG | Meningioma | — | 0.896 |
| 5 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.892 |
| 6 | BS_8J3B6ZB6 | pilocytic astrocytoma | — | 0.889 |
| 7 | SRR660895 | GTEX | — | 0.887 |
| 8 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.886 |
| 9 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.886 |
| 10 | SRR1388007 | GTEX | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.536 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.476 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.429 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.426 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.419 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.415 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.394 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.382 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.375 | Inavolisib | — uncovered |
| APOPTOSIS | 0.372 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.365 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.361 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.336 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.332 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.314 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.311 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.292 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.284 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.278 | Inavolisib | — uncovered |